Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Trial of plasmapheresis in ALS/MND registered (PALADIN2)

Original source

Trial of plasmapheresis in ALS/MND registered (PALADIN2)ClinicalTrials.gov · 24 July 2026 (opens in a new tab)

Trial at a glance

Status
Recruiting
Intervention
plasmapheresis (device)
Enrolment
20 participants (estimated)
Site
Taiwan
Sponsor
National Taiwan University Hospital
Registration
NCT07726563

Compass reports what the trial registry states. A trial being registered, recruiting or completed is not evidence that a treatment works.

PALADIN2 is a recruiting interventional study of plasmapheresis in people with amyotrophic lateral sclerosis who have an autoantibody against NRIP 2. The study is sponsored by National Taiwan University Hospital, has an estimated enrolment of 20 participants, and has a site listed in Taiwan. The registry change is that the trial has been registered.

Why this matters

This registration identifies a new ALS/MND trial in Taiwan and records it as recruiting. The registry does not provide further site details or results.

Trial updates

Trial registered — 24 July 2026

Compass began tracking this trial’s registry record on the date of its first update above. Changes before then are not listed.

Summarised by Compass 30 August 2026 · reported from Taiwan

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?